Toward the validation of functional neuroimaging as a potential biomarker for Alzheimer's Disease: Implications for drug development

Molecular Imaging and Biology

Volumn 7, Issue 1, 2005, Pages 59-68

  Pupi, Alberto ^a   Mosconi, Lisa ^a   Nobili, Flavio M ^b   Sorbi, Sandro ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Alzheimer's disease; Biomarker; Clinical trial; Drug development; Neuroimaging; PET; SPECT; Surrogate endpoint

Indexed keywords

AMYLOID; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; FLUORODEOXYGLUCOSE F 18; GLUCOSE; METRIFONATE; PLACEBO; RIVASTIGMINE; TRACER;

ALZHEIMER DISEASE; BIOLOGICAL ACTIVITY; BIOMEDICAL TECHNOLOGY ASSESSMENT; BRAIN BLOOD FLOW; BRAIN FUNCTION; BRAIN REGION; CLINICAL TRIAL; COGNITIVE DEFECT; DATA ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; EVIDENCE BASED MEDICINE; FRONTAL CORTEX; GENETIC RISK; GLUCOSE METABOLISM; HUMAN; MEDICAL LITERATURE; NEUROIMAGING; NEUROPATHOLOGY; NEUROPSYCHOLOGY; PARIETAL LOBE; PREDICTION; PRIORITY JOURNAL; PUBLICATION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STANDARDIZATION; TEMPORAL CORTEX; VALIDATION PROCESS;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; POSITRON-EMISSION TOMOGRAPHY; TREATMENT OUTCOME;

EID: 25144495717     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-005-0953-8     Document Type: Review

References (56)

1. L Fratiglioni D Ronchi De H Aguero-Torres 1999 Worldwide prevalence and incidence of dementia Drugs Aging 15 365-375
2. http://jin.jcic.or.jp/stat/stats/01CEN2C.html
3. R Brookmeyer S Gray C Kawas 1998 Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset Am J Public Health 88 1337-1342
4. G Blessed BE Tomlinson M Roth 1968 The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects Br J Psychiatry 114 797-811 1:STN:280:CCeA38bms1U%3D 5662937
5. WJ Meerding L Bonneux JJ Polder MA Koopmanschap PJ Maas van der 1998 Demographic and epidemiological determinants of healthcare costs in Netherlands: Cost of illness study Br Med J 317 111-115 1:STN:280:DyaK1czit1Wqsw%3D%3D
6. HM Fillit AW O'Connell WM Brown et al. 2002 Barriers to drug discovery and development for Alzheimer disease Alzheimer Dis Assoc Disord 16 Suppl 1 S1-S8 10.1097/00002093-200200001-00001
7. http://biomed.brown.edu/Courses/BI108/BI108_1999_Groups/ Neuroelectrodes_Te_Team/background.html#demographics
8. NR Cutler JJ Sramek 2001 Review of the next generation of Alzheimer's disease therapeutics: Challenges for drug development Prog Neuropsychopharmacol Biol Psychiatry 25 27-57 10.1016/ S0278-5846(00)00147-0
9. LD Altstiel 2002 Barriers to Alzheimer disease drug discovery and development in the biotechnology industry Alzheimer Dis Assoc Disord 16 Suppl 1 S29-S32 10.1097/00002093-200200001-00005
10. AJ Atkinson Jr 2001 Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework Clin Pharmacol Ther 69 89-95 10.1067/mcp.2001.113989
11. TE Golde 2003 Alzheimer disease therapy: Can the amyloid cascade be halted? J Clin Invest 111 11-18 10.1172/JCI200317527
12. Van Eldik LJ Alzheimer disease. Alzheimer Dis Assoc Disord 16(Suppl 1)
13. JC Mazziotta ME Phelps 1986 Principles and applications for the brain and heart In: ME Phelps JC Mazziotta H Schelbert (eds) Positron emission tomography and autoradiography Raven Press New York 493-579
14. KJ Friston AP Holmes KJ Worsley J-B Poline CD Frith RSJ Frackowiak 1995 Statistical parametric maps in functional imaging: A general linear approach Hum Brain Mapping 2 189-210
15. D Mildvan A Landay V Gruttola De SG Machado J Kagan 1997 An approach to the validation of markers for use in AIDS clinical trials Clin Infect Dis 24 764-774
16. RL Heertum Van RS Tikofsky 2003 Positron emission tomography and single-photon emission computed tomography brain imaging in the evaluation of dementia Semin Nucl Med 33 77-85 10.1053/snuc.2003.127294
17. S Minoshima NL Foster DE Kuhl 1994 Posterior cingulate cortex in Alzheimer's disease Lancet 344 89510.1016/S0140-6736(94)92871-1 1:STN:280:ByuA2snlslE%3D
18. K Herholz E Salmon D Perani et al. 2002 Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET NeuroImage 17 302-316 10.1006/nimg.2002.1208
19. DH Silverman GW Small CY Chang et al. 2001 Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome J Am Med Assoc 286 2120-2127 10.1001/jama.286.17.2120
20. K Palmer L Backman B Winblad L Fratiglioni 2003 Detection of Alzheimer's disease and dementia in the preclinical phase: Population based cohort study Br Med J 326 245
21. L Mosconi A Pupi MTR Cristofaro De M Fayyaz S Sorbi K Herholz 2004 Functional interactions of the entorhinal cortex. An FDG-PET study on normal aging and Alzheimer's disease J Nucl Med 45 382-392
22. H Braak E Braak 1991 Neuropathological staging of Alzheimer-related changes Acta Neuropathol (Berl) 82 239-259 10.1007/BF00308809
23. L Mosconi S Sorbi B Nacmias et al. 2003 Brain metabolic differences between sporadic and familial Alzheimer's disease Neurology 61 1138-1141
24. D Kogure H Matsuda T Ohnishi et al. 2000 Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT J Nucl Med 41 1155-1162 1:STN:280:DC%2BD3czpslemsA%3D%3D 10914904
25. P Bartenstein S Minoshima C Hirsch et al. 1997 Quantitative assessment of cerebral blood flow in patients with Alzheimer's disease by SPECT J Nucl Med 38 1095-1101 1:STN:280:ByiA28bjtV0%3D 9225797
26. WJ Jagust MN Haan JL Eberling N Wolfe BR Reed 1996 Functional imaging predicts cognitive decline in Alzheimer's disease J Neuroimaging 6 156-160
27. K Herholz A Nordberg E Salmon et al. 1999 Impairment of neocortical metabolism predicts progression in Alzheimer's disease Dement Geriatr Cogn Disord 10 494-504 10.1159/000017196
28. RC Petersen GE Smith SC Waring RJ Ivnik EG Tangalos E Kokmen 1999 Mild cognitive impairment: Clinical characterization and outcome Arch Neurol 56 303-308 10.1001/archneur.56.3.303 1:STN:280:DyaK1M3gsFSqtw%3D%3D 10190820
29. GW Small PV Rabins PP Barry et al. 1997 Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society J Am Med Assoc 278 1363-1371 10.1001/jama.278.16.1363 1:STN:280:DyaK1c%2FgtFKgtg%3D%3D
30. MJ Leon de A Convit OT Wolf et al. 2001 Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-deoxy-D-glucose/ positron-emission tomography (FDG/PET) Proc Natl Acad Sci U S A 98 10966-10971 10.1073/pnas.191044198
31. S Minoshima B Giordani S Berent KA Frey NL Foster DE Kuhl 1997 Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease Ann Neurol 42 85-94 1:STN:280:ByiA28bitVU%3D 9225689
32. A Drzezga N Lautenschlager H Siebner et al. 2003 Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: A PET follow-up study Eur J Nucl Med Mol Imaging 30 1104-1113 10.1007/s00259-003-1194-1
33. KA Johnson K Jones BL Holman et al. 1998 Preclinical prediction of Alzheimer's disease using SPECT Neurology 50 1563-1571 1:STN:280:DyaK1c3psFCmsA%3D%3D 9633695
34. H Hanyu T Shimizu Y Tanaka M Takasaki K Koizumi K Abe 2003 Regional cerebral blood flow patterns and response to donepezil treatment in patients with Alzheimer's disease Dement Geriatr Cogn Disord 15 177-182 10.1159/000068785
35. RN Rosenberg 2000 The molecular and genetic basis of AD: The end of the beginning. The 2000 Wartenberg lecture Neurology 54 2045-2054
36. GW Small LM Ercoli DH Silverman et al. 2000 Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease Proc Natl Acad Sci U S A 97 6037-6042 10.1073/pnas.090106797
37. EM Reiman RJ Caselli K Chen GE Alexander D Bandy J Frost 2001 Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease Proc Natl Acad Sci U S A 98 3334-3339 10.1073/pnas.061509598
38. L Mosconi S Sorbi B Nacmias et al. 2004 Brain metabolic decreases related to the dose of the APOE E4 allele in Alzheimer's disease J Neurol Neurosurg Psychiatry 75 370-376 10.1136/jnnp.2003.014993
39. B Reisberg R Doody A Stoffler F Schmitt et al. 2003 Memantine in moderate-to-severe Alzheimer's disease N Engl J Med 348 14 1333-1341 10.1056/NEJMoa013128
40. PN Tariot MR Farlow GT Grossberg et al. 2004 Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial JAMA 291 317-324 10.1001/ jama.291.3.317
41. WE Klunk H Engler A Nordberg et al. 2004 Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B Ann Neurol 55 306-319 10.1002/ana.20009 1:CAS:528:DC%2BD2cXisFKntb8%3D 14991808
42. MS Mega JL Cummings SM O'Connor et al. 2001 Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease Neuropsych Neuropsychol Behav Neurol 14 38-63
43. S Nakano T Asada H Matsuda M Uno M Takasaki 2001 Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease J Nucl Med 42 1441-1445
44. L Tune PJ Tiseo J Ieni et al. 2003 Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: Results of a 24-week, double-blind, placebo-controlled study Am J Geriatr Psychiatry 11 169-177 10.1176/appi.ajgp.11.2.169
45. F Nobili P Vitali M Canfora et al. 2002 Effects of long-term donepezil therapy on rCBF of Alzheimer's patients Clin Neurophysiol 113 1241-1248 10.1016/S1388-2457(02)00110-4
46. SG Potkin R Anand K Fleming et al. 2001 Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease Int J Neuropsychopharmacol 4 223-230 10.1017/S1461145701002528
47. R Frank R Hargreaves 2003 Clinical biomarkers in drug discovery and development Nat Rev Drug Discov 2 566-580 10.1038/nrd1130
48. F Nobili M Koulibaly P Vitali et al. 2002 Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors J Nucl Med 43 983-990
49. A Venneri MF Shanks RT Staff et al. 2002 Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease NeuroReport 13 83-87 10.1097/00001756-200201210-00020
50. http://www.fda.gov/cder/audiences/acspage/peripheralmeetings1.htm
51. GE Alexander K Chen P Pietrini SI Rapoport EM Reiman 2002 Longitudinal PET evaluation of cerebral metabolic decline in dementia: A potential outcome measure in Alzheimer's Disease treatment studies Am J Psychiatry 159 738-745 10.1176/appi.ajp.159.5.738 11986126
52. DF Moore G Altarescu WC Barker et al. 2003 White matter lesions in Fabry disease occur in 'prior' selectively hypometabolic and hyperperfused brain regions Brain Res Bull 62 231-240 10.1016/ j.brainresbull.2003.09.021
53. M Bobinski MJ Leon De A Convit et al. 1999 MRI of entorhinal cortex in mild Alzheimer's Disease Lancet 353 38-40 1:STN:280:DyaK1M7ks1Glsg%3D%3D
54. X Shao ER Butch MR Kilbourn et al. 2003 N-[(18)F]Fluoroethylpiperidinyl, N-[(18)F]fluoroethylpiperidinemethyl and N-[(18)F]fluoroethylpyrrolidinyl esters as radiotracers for acetylcholinesterase Nucl Med Biol 30 5 491-500 10.1016/ S0969-8051(03)00031-3 Jul
55. 123I]CNS 1261 - a potential SPET tracer for the NMDA receptor Nucl Med Biol 30 441-454 10.1016/S0969-8051(02)00450-X
56. A Nordberg 2001 Nicotinic receptor abnormalities of Alzheimer's disease: Therapeutic implications Biol Psychiatry 49 200-210 10.1016/ S0006-3223(00)01125-2